SELDI技术预测FOLFIRI方案治疗结肠癌疗效敏感性的应用研究  

An Applied Study on Estimating the Sensitivity of Curative Effect in Treating Colon Cancer with FOLFIRI Plan by SELDI

作　　者：郭琴琴[1] 裴毅[2] 范亚峰[3] 

机构地区：[1]山西医科大学研究生学院,山西太原030001 [2]山西医学科学院 [3]山西省肿瘤医院

出　　处：《中国医学创新》2012年第13期17-19,共3页Medical Innovation of China

摘　　要：目的:应用SELDI技术发现预测FOLFIRI方案治疗晚期结肠癌患者疗效敏感性的界定指纹,探索新的用药指征。方法:选择12例行FOLFIRI方案化疗,并有可观察疗效的晚期结肠癌术后患者,应用表面增强飞行时间质谱(SELDI-TOF-MS)技术在化疗前对患者的血清样本进行检测,根据RECIST实体肿瘤疗效评价标准将FOLFIRI方案治疗1疗程(3周期)后2周～3个月内的患者分成稳定组(SD)和无效组(PD)。应用ProteinChip3.2.0和Biomarker Wizard3.1软件分析两组之间有显著差异的指纹(峰型及丰度)并进行比较。结果:术后稳定组与无效组相比有3个蛋白质峰有显著差异性,M/Z分别为1372、1698、1865,与稳定组相比,无效组上调的峰M/Z为1372和1698,下调的峰M/Z为1865。结论:应用SELDI技术可以获得预测FOLFIRI方案治疗结肠癌疗效敏感性的标识指纹,其M/Z为:1372±50H+、1698±50H+、1865±50H+。其中M/Z:1372±50H+丰度<10、1698±50H+丰度<5、1865±50H+丰度>10为预计FOLFIRI方案治疗结肠癌可获得稳定的标识指纹;其M/Z:1372±50H+丰度≥10、1698±50H+丰度≥5、1865±50H+丰度≤10为预计FOLFIRI方案治疗结肠癌无效的标识指纹。Objective ：To discover proteomic Define fingerprint which can be used to estimate the sensitivity of curative effect in treating Colon cancer with FOLFIRI plan and explore the indications of using the drug by SELDI. Methods ：Collected and deteeted the serum of 12 colon cancer patients who had received surgery and FOLFIRI plan and had the observed curative effect before chemotherapy by SELDI-TOE-MS（surface-enhanced laser desorption/ionization time-of-flight mass spectrometry） technique. Observed these patients after application of FOLFIRI from 2 weeks to 3 months. According to the Response Evaluation Criteria In Solid Tumor（RECIST, 2000）, the 12 patients were divided into 2 groups, Stable group（6 cases, SD） and inefficacy group（6 cases, PD）.Compared significant differences of the fingerprints between stable group and inefficacy group with Biomarker Wizard Software. Results ：There were 3 significant different protein fingerprints between the two groups , M/Z were 1372, 1698, 1865, compared with stable group, MIZ ：1372, 1698 were height and M/Z ：1865 was lower in inefficacy group. Conclusion ：Author could estimate the sensitivity of curative effect in treating colon cancer with FOLFIRI Plan by obtaining their protein fingerprints. There are 3 significant different protein fingerprints between Stable and inefficacy group , M/Z were 1204, 2868, 4176. If the abundance of M/Z ： 1372＋50H＋〈10, 1698-＋ 50H＋〈5, 1865 ＋50H＋〉10, it may be attributed to stable group, otherwise, it belonge to inefficacy group.

关 键 词：表面增强激光解吸电离-飞行时间质谱技术 蛋白质指纹 FOLFIRI方案 结肠癌 

分 类 号：R735.35[医药卫生—肿瘤]